Multiple Myeloma | Topics

The FDA lifted the clinical hold on the phase 1 MELANI-01 trial, which is evaluating UCARTCS1 for the treatment of patients with relapsed or refractory multiple myeloma.

“The most important takeaway here is that bridging radiation doesn’t appear to increase the risk of [cytokine release syndrome; CRS] or neurotoxicity,” said lead study author Shwetha Manjunath, MD.

Genmab recently announced positive topline results from part 2 of the Phase 3 CASSIOPEIA study examining daratumumab monotherapy as maintenance therapy to treat patients diagnosed with multiple myeloma.